WO2003064668A1 - Nouveau micro-organisme, son produit et utilisation associee - Google Patents
Nouveau micro-organisme, son produit et utilisation associee Download PDFInfo
- Publication number
- WO2003064668A1 WO2003064668A1 PCT/JP2003/000851 JP0300851W WO03064668A1 WO 2003064668 A1 WO2003064668 A1 WO 2003064668A1 JP 0300851 W JP0300851 W JP 0300851W WO 03064668 A1 WO03064668 A1 WO 03064668A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- medium
- compound
- cells
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/46—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention has a melanin production inhibitory action based on tyrosinase inhibitory activity, and is a novel compound effective in preventing and improving pigmentation, spots, freckles, and liver spots after sunburn (
- melanin is produced by enzymatic or non-enzymatic oxidative action from dopadopaquinone produced by the action of the enzyme tyrosinase, and inhibiting this process is also effective in suppressing melanin production.
- Representative drugs include ascorbic acid and hydroquinone.
- FIG. 3 shows the 13 C-NMR spectrum of the compound of the present invention.
- This strain is a gram-negative rod and has motility due to polar flagella.
- the size of the cells is 0.8-1.1.1 X1.0-2.2 m. No spore formation is observed 2)
- Cultural properties are 0.8-1.1.1 X1.0-2.2 m. No spore formation is observed 2)
- this strain is a gram-negative facultative anaerobic bacillus with motility.
- the growth temperature range is 10-37 ° C, and nitrate reduction, denitrification reaction, MR test, availability of citric acid, and positive force test are positive.
- the results of the OF test is fermented.
- the results of the VP test the production of indole, the production of hydrogen sulfide, the urease and oxidase tests, and the arginine decomposition reaction are negative.
- the strain was deposited at the National Institute of Advanced Industrial Science and Technology (AIST) at the Patent Organism Depositary Center (1-1, Tsukuba-Higashi, Ibaraki, Japan, 1-Chuo-No. 6) on December 25, 2001. Deposited as FE RM P-186 6 6 and requested to be transferred to a deposit under the Budapest Treaty on February 26, 2000, accession number FE RM BP- 8 26 6 Has been commissioned.
- AIST National Institute of Advanced Industrial Science and Technology
- FE RM P-186 6 6 Deposited as FE RM P-186 6 6 and requested to be transferred to a deposit under the Budapest Treaty on February 26, 2000, accession number FE RM BP- 8 26 6 Has been commissioned.
- the Enterobacter sp. B20 strain used in the present invention includes, in addition to microorganisms isolated from nature, Needless to say, this includes not only mutants artificially mutated by ultraviolet rays, X-rays, chemical agents and the like but also natural mutants.
- the substance in the culture is extracted from the culture as it is, or by adding a water-immiscible organic solvent such as ethyl acetate to the culture obtained by centrifugation or by adding a filter aid to the culture and filtering. I do.
- the substance can be extracted by appropriately bringing the culture solution into contact with a carrier, adsorbing the produced substance in the filtrate, and then eluting with a suitable solvent.
- the fraction containing the substance obtained using each of the above procedures is subjected to column chromatography using silica gel, ODS, etc., centrifugal liquid separation chromatography, high performance liquid chromatography using ODS (HPLC). It is possible to separate and purify more purely by such a standard method. That is, separation and purification are carried out by means used in the production of general physiologically active substances utilizing the difference in solubility and solubility in an appropriate solvent, using the melanin production inhibitory activity as an index. These methods can be used alone as needed or combined in any order and applied repeatedly.
- the compound (I) of the present invention forms a salt with an acid.
- the external preparation for skin of the present invention includes, in addition to the compound (I) of the present invention or a salt thereof, various optional components used in ordinary cosmetics, quasi-drugs, pharmaceuticals, etc., for example, oils, humectants, thickeners Agents, preservatives, emulsifiers, pigments, powders, pH adjusters, medicinal ingredients, ultraviolet absorbers, antioxidants, fragrances, etc. can be appropriately compounded.
- oils, humectants, thickeners Agents, preservatives, emulsifiers, pigments, powders, pH adjusters, medicinal ingredients, ultraviolet absorbers, antioxidants, fragrances, etc. can be appropriately compounded.
- the cells were resuspended in 0.05M phosphate buffer (pH 6.8), and the cells were crushed on ice using a homogenizer. 1. An equal volume of the cell solution was dispensed into a 5 ml sample tube, and centrifuged at 4 ° C, 12000 rpm for 15 minutes. Collect the supernatant Stored on ice until use (crude enzyme solution).
- L-dopa was adjusted to 0.8 mg / ml with 0.05M phosphate buffer (pH 6.8). Add 0.25 ml of L-dopa solution, 0.25 m of the compound of the present invention (I) at various concentrations, add 0.5 ml of the crude enzyme solution, mix quickly, and incubate at 25 ° C for 2 hours. The absorbance at 475 nm was measured.
- aqueous phase and alcohol phase prepared according to the formulations shown in Tables 5 and 6 below were mixed and solubilized in the exposed upper arm skin of the subject. Each sample prepared as described above was applied once in the morning and evening for 4 weeks.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002474467A CA2474467A1 (en) | 2002-01-30 | 2003-01-29 | Novel microorganism, its product and utilization thereof |
US10/502,949 US7115721B2 (en) | 2002-01-30 | 2003-01-29 | Microorganism, its product and utilization thereof |
EP20030734623 EP1469080A1 (en) | 2002-01-30 | 2003-01-29 | Novel microorganism, its product and utilization thereof |
JP2003564259A JPWO2003064668A1 (ja) | 2002-01-30 | 2003-01-29 | 新規微生物、その産生物及びその利用 |
KR10-2004-7011703A KR20040088044A (ko) | 2002-01-30 | 2003-01-29 | 신규 미생물, 그의 생산물 및 그의 이용 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-20981 | 2002-01-30 | ||
JP2002020981 | 2002-01-30 | ||
JP2002-21224 | 2002-01-30 | ||
JP2002021224 | 2002-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003064668A1 true WO2003064668A1 (fr) | 2003-08-07 |
Family
ID=27667446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/000851 WO2003064668A1 (fr) | 2002-01-30 | 2003-01-29 | Nouveau micro-organisme, son produit et utilisation associee |
Country Status (7)
Country | Link |
---|---|
US (1) | US7115721B2 (ja) |
EP (1) | EP1469080A1 (ja) |
JP (1) | JPWO2003064668A1 (ja) |
KR (1) | KR20040088044A (ja) |
CN (1) | CN1625599A (ja) |
CA (1) | CA2474467A1 (ja) |
WO (1) | WO2003064668A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004100962A1 (ja) * | 2003-05-15 | 2004-11-25 | Akira Nakagawa | メラニン産生抑制物資 |
KR101891234B1 (ko) | 2016-09-06 | 2018-08-24 | 전남대학교산학협력단 | 신규 프로테아제 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404661A2 (fr) * | 1989-06-20 | 1990-12-27 | Roussel Uclaf | Utilisation de lipopolysaccharides extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau |
CA2027723A1 (fr) * | 1989-10-17 | 1991-04-18 | Armelle Bonfils | Utilisation de glycoproteines extraites de bacteries gram (-) pour la fabrication de compositions cosmetiques ou dermatologiques et compositions les renfermant |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001342110A (ja) * | 2000-06-02 | 2001-12-11 | Ezaki Glico Co Ltd | 皮膚外用剤 |
-
2003
- 2003-01-29 WO PCT/JP2003/000851 patent/WO2003064668A1/ja not_active Application Discontinuation
- 2003-01-29 CA CA002474467A patent/CA2474467A1/en not_active Abandoned
- 2003-01-29 CN CNA03802926XA patent/CN1625599A/zh active Pending
- 2003-01-29 EP EP20030734623 patent/EP1469080A1/en not_active Withdrawn
- 2003-01-29 US US10/502,949 patent/US7115721B2/en not_active Expired - Fee Related
- 2003-01-29 JP JP2003564259A patent/JPWO2003064668A1/ja not_active Ceased
- 2003-01-29 KR KR10-2004-7011703A patent/KR20040088044A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0404661A2 (fr) * | 1989-06-20 | 1990-12-27 | Roussel Uclaf | Utilisation de lipopolysaccharides extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau |
CA2027723A1 (fr) * | 1989-10-17 | 1991-04-18 | Armelle Bonfils | Utilisation de glycoproteines extraites de bacteries gram (-) pour la fabrication de compositions cosmetiques ou dermatologiques et compositions les renfermant |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004100962A1 (ja) * | 2003-05-15 | 2004-11-25 | Akira Nakagawa | メラニン産生抑制物資 |
KR101891234B1 (ko) | 2016-09-06 | 2018-08-24 | 전남대학교산학협력단 | 신규 프로테아제 |
Also Published As
Publication number | Publication date |
---|---|
CA2474467A1 (en) | 2003-08-07 |
US20050063927A1 (en) | 2005-03-24 |
US7115721B2 (en) | 2006-10-03 |
CN1625599A (zh) | 2005-06-08 |
EP1469080A1 (en) | 2004-10-20 |
KR20040088044A (ko) | 2004-10-15 |
JPWO2003064668A1 (ja) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160141205A (ko) | 신규한 락토바실러스 속 균주 및 그 배양액을 유효성분으로 함유하는 화장료 조성물 | |
KR20140008684A (ko) | 신규의 락토바실러스 퍼멘텀 균주, 이를 이용한 화장료 조성물 및 그 제조방법 | |
US8592378B2 (en) | Compound WS 727713 | |
WO2023132415A1 (ko) | 유산균 복합 균주를 유효성분으로 포함하는 피부 주름 개선, 보습, 피부 장벽 강화 및 피부 재생용 조성물 | |
WO2003064668A1 (fr) | Nouveau micro-organisme, son produit et utilisation associee | |
JP2007070305A (ja) | 養毛・育毛剤 | |
JPH05194258A (ja) | メラニン色素合成阻害剤 | |
KR100271997B1 (ko) | Fa-70d물질, 이를 생산하기 위한 방법 및 그 용도 | |
KR20180041351A (ko) | 수염틸란드시아 발효액을 포함하는 피부 미백용 화장료 조성물 | |
KR20210119794A (ko) | 알터로모나스 속 균주 및 이를 포함하는 미백용 조성물 | |
EP1160330B1 (en) | Substances wk-5344a and wk-5344b and process for producing the same | |
KR20110105243A (ko) | 녹두 발효-효소 추출액을 포함하는 피부 미백용 화장료 조성물 | |
KR102499330B1 (ko) | 콤부차로부터 분리된 균주의 복합 배양물을 함유하는 피부장벽 강화용 화장료 조성물 | |
KR102298453B1 (ko) | 셀로움 발효액을 포함하는 피부 미백용 화장료 조성물 | |
KR102349785B1 (ko) | 안트라닐산을 유효성분으로 하는 피부 미백용 조성물 | |
US20240207169A1 (en) | Composition for improving skin wrinkle, moisturizing, strengthening skin barrier, and promoting skin regeneration, comprising mixed lactic acid bacteria as active ingredient | |
KR20210137848A (ko) | 미백 활성을 가지는 슈도알테로모나스속 roa-050 균주 및 그의 용도 | |
JP2557070B2 (ja) | 新規生理活性物質プロベスチン、プロスタチン及びその製造法 | |
JP2008007455A (ja) | 新規発酵生産物 | |
WO2001046451A1 (fr) | Migrastatine, procede de production et compositions medicales correspondants | |
KR20230091552A (ko) | 지아잔틴을 포함하는 펄비비르가 tsd2061 균주 및 이를 이용한 지아잔틴 생산 방법 | |
KR20230169718A (ko) | 신규 아이에미아씨에와과 미생물 및 이의 용도 | |
JPH05255389A (ja) | サイクロペプチド化合物 | |
JP5013886B2 (ja) | 新規ロンギシクレン誘導体および当該誘導体を含むチロシナーゼ活性阻害剤 | |
JPH05310727A (ja) | 生理活性物質コウジ酸ダイマー、その製造方法および生理活性物質コウジ酸ダイマーを有効成分とする美白剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003734623 Country of ref document: EP Ref document number: 2474467 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047011703 Country of ref document: KR Ref document number: 2003802926X Country of ref document: CN Ref document number: 10502949 Country of ref document: US Ref document number: 2003564259 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003734623 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003734623 Country of ref document: EP |